AUD $3.7M Income Tax Refund Received
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The company expects to receive additional non-dilutive funds and is preparing for a Share Purchase Plan to raise further capital. Recce Pharmaceuticals is focused on developing a new class of synthetic anti-infectives to combat antibiotic-resistant infections.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Placement & SPP to raise $8 million
- HREC Approval Accelerates Global Phase 3 DFI Strategy
- Addendum to Recce Signs Middle East Licensing Term Sheet
- Recce Signs Middle East Licensing Term Sheet
- Brazil Patent Granted for RECCE Anti-Infectives
Later from Recce Pharmaceuticals
- Vietnamese Patent Granted for RECCE Anti-Infectives
- HREC Approves Comparator Study for Pivotal Phase 3 DFI
- Appendix 4E and FY26 Annual Report
- Amendments to Debt Facility with Avenue Capital Group
- Independent Review of Indonesian Phase 3 R327G Trial Data
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals